AstraZeneca reported higher revenue and continued pipeline momentum in its H1 and Q2 2026 results, supported by growth across its core therapy areas and additional regulatory and clinical progress. The company said total revenue rose to more than $15 billion in the first quarter of 2026, driven by Oncology and Rare Disease, and reconfirmed its full-year guidance for 2026.
The company’s investor materials said AstraZeneca continues to move through a catalyst-rich period, with multiple Phase 3 readouts and new approvals across major regions since its previous results update. Management highlighted that the company remains focused on execution across its core businesses while building out its late-stage pipeline.
AstraZeneca’s earlier 2026 update pointed to strong commercial performance, including double-digit growth in product revenue and continued gains from its alliance revenue. It also reiterated expectations for full-year revenue growth in the mid- to high-single digits and core EPS growth in the low double digits, based on constant exchange rates. The core tax rate guidance remained unchanged at 18% to 22%.
The company said it planned to publish its H1 and Q2 2026 results on July 27, 2026, with an accompanying investor webcast and presentation. AstraZeneca’s results materials were also listed on its investor relations pages alongside prior quarterly announcements and presentations.
The update comes as AstraZeneca continues to emphasize both commercial execution and development progress across oncology, rare disease, and other key areas. The company has framed 2026 as a year of significant clinical catalysts and regulatory activity, with the first half reflecting that broader strategy.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!